VA
EW icon

Vident Advisory’s Edwards Lifesciences EW Stock Holding History

Vident Advisory’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.6M Sell
394,076
-24,816
-6% -$2.08M 0.26% 79
2026
Q1 		$33.5M Buy
418,892
+31,310
+8% +$2.58M 0.29% 67
2025
Q4 		$33M Sell
387,582
-25,028
-6% -$2.05M 0.3% 70
2025
Q3 		$32.1M Buy
412,610
+80,531
+24% +$6.29M 0.31% 71
2025
Q2 		$26M Buy
332,079
+43,359
+15% +$3.23M 0.29% 82
2025
Q1 		$20.9M Sell
288,720
-6,663
-2% -$477K 0.31% 73
2024
Q4 		$21.9M Buy
295,383
+285,661
+2,938% +$20M 0.38% 57
2024
Q3 		$642K Sell
9,722
-1,736
-15% -$126K 0.02% 811
2024
Q2 		$1.06M Buy
11,458
+831
+8% +$73.6K 0.03% 579
2024
Q1 		$1.02M Sell
10,627
-4,494
-30% -$378K 0.02% 567
2023
Q4 		$1.15M Buy
15,121
+20
+0.1% +$1.39K 0.03% 520
2023
Q3 		$1.05M Buy
+15,101
New +$1.21M 0.03% 493

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Vident Advisory's EW Position: Q2 2026 in Review

Vident Advisory reduced its Edwards Lifesciences (EW) stake by 5.9% in Q2 2026, selling an estimated $2.08M and leaving 394,076 shares worth $35.6M. The position accounts for 0.26% of the portfolio, ranked #79.

Vident Advisory first reported a position in EW in Q3 2023 and has held it in 12 quarters since. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Vident Advisory held 394,076 shares of Edwards Lifesciences worth $35.6M as of Q2 2026.
  • Vident Advisory sold 24,816 Edwards Lifesciences shares in Q2 2026, an estimated $2.08M.
  • Edwards Lifesciences made up 0.26% of Vident Advisory's portfolio in Q2 2026, its #79 holding.
  • Vident Advisory first reported a position in Edwards Lifesciences in Q3 2023 and has held it in 12 quarters since.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.